Literature DB >> 20495084

Medullary thyroid carcinoma: management of lymph node metastases.

Jeffrey F Moley1.   

Abstract

Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy of the thyroid C cells. Metastatic spread commonly occurs to cervical and mediastinal lymph nodes. MTC cells do not concentrate radioactive iodine and are not sensitive to hormonal manipulation. Surgery is currently the only therapy that can reliably lead to cure, reduction in tumor burden, or effective palliation. In patients with hereditary MTC, central lymph node dissection should be considered in preventative operations if the calcitonin level is elevated. Systematic surgical removal of at-risk or involved lymph node basins (compartmental dissection) should be performed in all patients with palpable primary tumors and recurrent disease. A "berry-picking" approach is discouraged. Although data are limited, standard chemotherapy and radiation therapy have not been shown to be effective in the treatment of MTC. Newer targeted drug therapies are promising and are being examined in therapeutic clinical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20495084     DOI: 10.6004/jnccn.2010.0042

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  18 in total

Review 1.  Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.

Authors:  C M Thomas; S L Asa; S Ezzat; A M Sawka; D Goldstein
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 3.  Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.

Authors:  Samuel A Wells
Journal:  Endocr Relat Cancer       Date:  2017-11-15       Impact factor: 5.678

4.  EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.

Authors:  Luca Giovanella; Giorgio Treglia; Ioannis Iakovou; Jasna Mihailovic; Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-04       Impact factor: 9.236

5.  Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience.

Authors:  Anish Jacob Cherian; Pooja Ramakant; Rekha Pai; Marie Therese Manipadam; S Elanthenral; Anuradha Chandramohan; Julie Hephzibah; David Mathew; Dhukabandhu Naik; Thomas V Paul; Simon Rajaratnam; Nihal Thomas; M J Paul; Deepak Thomas Abraham
Journal:  Indian J Surg Oncol       Date:  2017-12-08

6.  Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.

Authors:  Jian Yu Xu; William A Murphy; Denái R Milton; Camilo Jimenez; Sarika N Rao; Mouhammed Amir Habra; Steven G Waguespack; Ramona Dadu; Robert F Gagel; Anita K Ying; Maria E Cabanillas; Steven P Weitzman; Naifa L Busaidy; Rena V Sellin; Elizabeth Grubbs; Steven I Sherman; Mimi I Hu
Journal:  J Clin Endocrinol Metab       Date:  2016-09-23       Impact factor: 5.958

7.  Are there disparities in the presentation, treatment and outcomes of patients diagnosed with medullary thyroid cancer?-An analysis of 634 patients from the California Cancer Registry.

Authors:  Christine Cox; Yingjia Chen; Rosemary Cress; Alison M Semrad; Thomas Semrad; Jessica E Gosnell; Michael J Campbell
Journal:  Gland Surg       Date:  2016-08

8.  ATF4 loss of heterozygosity is associated with poor overall survival in medullary thyroid carcinoma.

Authors:  Michelle D Williams; Junsheng Ma; Elizabeth G Grubbs; Robert F Gagel; Rozita Bagheri-Yarmand
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

9.  Medullary thyroid cancer: epidemiological pattern and factors contributing to recurrence and metastasis.

Authors:  O Hamdy; S Awny; I H Metwally
Journal:  Ann R Coll Surg Engl       Date:  2020-04-01       Impact factor: 1.891

Review 10.  Vandetanib: in medullary thyroid cancer.

Authors:  James E Frampton
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.